Aspirin is first-line treatment for migraine and episodic tension-type headache regardless of headache intensity

Headache

Volumn 52, Issue 1, 2012, Pages 48-56

  Lampl, Christian ^a   Voelker, Michael ^b   Steiner, Timothy J ^c  

^a Konventhospital Barmherzige Brueder ^*  (Austria)

^b BAYER PHARMA AG   (Germany)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

aspirin; migraine; stepped care; stratified care; tension type headache

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; SUMATRIPTAN;

ANALGESIA; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; EPISODIC TENSION HEADACHE; HUMAN; MIGRAINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CLINICAL TRIALS AS TOPIC; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TENSION-TYPE HEADACHE; TREATMENT OUTCOME; TRYPTAMINES;

EID: 84856253603     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.01974.x     Document Type: Article

References (52)

1. Diener HC, Bussone G, de Liano H, et al,. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004; 24: 947-954. (Pubitemid 39471921)
2. Diener HC, Eikermann A, Gessner U, et al,. Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. Eur Neurol. 2004; 52: 50-56. (Pubitemid 39077816)
3. Lange R, Schwarz JA, Hohn M,. Acetylsalicylic acid effervescent 1000 mg (Aspirin) in acute migraine attacks; a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia. 2000; 20: 663-667. (Pubitemid 32269464)
4. Lampl C, Voelker M, Diener HC,. Efficacy and safety of 1,000 mg effervescent aspirin: Individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol. 2007; 254: 705-712. (Pubitemid 47012463)
5. Lipton RB, Goldstein J, Baggish JS, Yataco AR, Sorrentine JV, Quiring SN,. Aspirin is efficacious for the treatment of acute migraine. Headache. 2005; 45: 283-292. (Pubitemid 40530192)
6. Diener HC, Lampl C, Reimnitz P, Voelker M,. Aspirin in the treatment of acute migraine attacks. Expert Rev Neurother. 2006; 6: 563-573. (Pubitemid 43764754)
7. Tfelt-Hansen P,. Triptans vs other drugs for acute migraine. Are there differences in efficacy? A comment. Headache. 2008; 48: 601-605. (Pubitemid 351467624)
8. Martínez-Martín P, Raffaelli E, Titus F, et al,. Efficacy and safety of metamizol vs. acetylsalicylic acid in patients with moderate episodic tension-type headache: A randomized, double-blind, placebo- and active-controlled, multicentre study. Cephalalgia. 2001; 21: 604-610. (Pubitemid 32661009)
9. Steiner TJ, Lange R, Voelker M,. Aspirin in episodic tension-type headache: Placebo-controlled dose-ranging comparison with paracetamol. Cephalalgia. 2003; 23: 59-66. (Pubitemid 36356807)
10. Steiner TJ, Paemeleire K, Jensen R, et al,. Couturier EGM on behalf of the European Headache Federation and Lifting The Burden: The Global Campaign to Reduce the Burden of Headache Worldwide. European principles of management of common headache disorders in primary care. J Headache Pain. 2007; 8 (Suppl. 1): 3-21.
11. British Association for the Study of Headache. Guidelines for All Healthcare Professionals in the Diagnosis and Management of Migraine, Tension-Type, Cluster and Medication-Overuse Headache, 3rd edn (1st revision). London: BASH; 2010. Available at: (accessed 18 March 2011).
12. Haag G, Diener HC, May A, et al,. Self-medication of migraine and tension-type headache: Summary of the evidence-based recommendations of the Deutsche Migräne und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft für Neurologie (DGN), the Ã-sterreichische Kopfschmerzgesellschaft (Ã-KSG) and the Schweizerische Kopfwehgesellschaft (SKG). J Headache Pain. 2011; 12: 201-217.
13. World Health Organization. WHO Model List of Essential Medicines. 16th list, updated 2010, p 15. Geneva: WHO; 2010. Available at: (accessed 18 March 2011).
14. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB,. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002; 22: 633-658. (Pubitemid 36609333)
15. Pryse-Phillips WE, Dodick DW, Edmeads JG, et al,. Guidelines for the diagnosis and management of migraine in clinical practice. CMAJ. 1997; 156: 1273-1287. (Pubitemid 27223150)
16. Silberstein SD,. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2000; 55: 754-762.
17. Evers S, Afra J, Frese A, et al,. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol. 2009; 16: 968-981.
18. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia. 2000; 20: 765-786.
19. International Conference on Harmonization (ICH) Topic E 6. Guideline for Good Clinical Practice. July 2002 CPMP/ICH/135/95.
20. Data on file. Study IMP S98-073. Bayer HealthCare Product Report No. PH-35230, 2008-1-18.
21. Data on file. Study IMP S98-074. Bayer HealthCare Product Report No. PH-35234, 2008-1-21.
22. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd Edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
23. Skovlund E, Flaten O,. Response measures in the acute treatment of migraine. Cephalalgia. 1995; 15: 519-522.
24. Lines CR, Vandormael K, Malbecq W,. A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients. Pain. 2001; 93: 185-190. (Pubitemid 32568404)
25. Stovner LJ, Hagen K, Jensen R, et al,. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia. 2007; 27: 193-210. (Pubitemid 46354128)
26. Lipton RB,. Disability assessment as a basis for stratified care. Cephalalgia. 1998; 18 (Suppl. 22): 40-46.
27. Stewart WF, Lipton RB, Whyte J, et al,. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology. 1999; 53: 988-994. (Pubitemid 29442114)
28. Stewart WF, Lipton RB, Dowson AJ, Sawyer J,. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001; 56 (Suppl. 1): 20-28.
29. Lipton RB, Stewart WF, Stone AM, Lainez MJ, Sawyer JP,. Disability in Strategies of Care Study Group. Stratified care vs step care strategies for migraine: The Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA. 2000; 284: 2599-2605.
30. Williams P, Dowson AJ, Rapoport AM, Sawyer J,. The cost effectiveness of stratified care in the management of migraine. Pharmacoeconomics. 2001; 19: 819-829. (Pubitemid 32758546)
31. Sculpher M, Millson D, Meddis D, Poole L,. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study. Pharmacoeconomics. 2002; 20: 91-100. (Pubitemid 34275758)
32. Cady RK, Lipton RB, Hall C, Stewart WF, O'Quinn S, Gutterman D,. Treatment of mild headache in disabled migraine sufferers: Results of the Spectrum Study. Headache. 2000; 40: 792-797. (Pubitemid 32053239)
33. Cady RK, Sheftell F, Lipton RB, et al,. Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials. Clin Ther. 2000; 22: 1035-1048.
34. Cady RK, Sheftell F, Lipton RB, Kwong WJ, O'Quinn S,. Economic implications of early treatment of migraine with sumatriptan tablets. Clin Ther. 2001; 23: 284-291. (Pubitemid 32231119)
35. Halpern MT, Lipton RB, Cady RK, Kwong WJ, Marlo KO, Batenhorst AS,. Costs and outcomes of early versus delayed migraine treatment with sumatriptan. Headache. 2002; 42: 984-999. (Pubitemid 35470706)
36. Pascual J, Cabarrocas X,. Within-patient early versus delayed treatment of migraine attacks with almotriptan: The sooner the better. Headache. 2002; 42: 28-31. (Pubitemid 34136608)
37. Mathew N,. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache. 2003; 43: 1075-1079. (Pubitemid 37543074)
38. Winner P, Mannix LK, Putnam DG, et al,. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2. Randomized, double-blind, placebo controlled studies. Mayo Clin Proc. 2003; 78: 1214-1222. (Pubitemid 37193512)
39. Dowson AJ, Massiou H, Lainez JM, Caborrocas X,. Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache. 2004; 44: 318-322. (Pubitemid 38541834)
40. Carpay J, Schoenen J, Ahmad F, Kinrade F, Boswell D,. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: Results of a multicenter, randomized, placebo-controlled study. Clin Ther. 2004; 26: 214-223. (Pubitemid 38339013)
41. Mathew NT, Kailasam J, Meadors L,. Early treatment of migraine with rizatriptan: A placebo-controlled study. Headache. 2004; 44: 669-673. (Pubitemid 38931897)
42. Klapper J, Lucas C, Rosio O,. Charlesworth B on behalf of the ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia. 2004; 24: 918-924. (Pubitemid 39471916)
43. Cady R, Elkind A, Goldstein J, Keywood C,. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin. 2004; 20: 1465-1472. (Pubitemid 39361351)
44. Scholpp J, Schellenberg R, Moeckesch B, Banik N,. Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. Cephalalgia. 2004; 24: 925-933. (Pubitemid 39471917)
45. Ferrari MD,. Should we advise patients to treat migraine attacks early? Cephalalgia. 2004; 24: 915-918.
46. Burstein R, Collins B, Jakubowski M,. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol. 2004; 55: 19-26. (Pubitemid 38067357)
47. Burstein R, Jakubowski M,. Analgesic triptan action in an animal model of intracranial pain: A race against the development of central sensitization. Ann Neurol. 2004; 55: 27-36. (Pubitemid 38067358)
48. Schieroni F, Bussone G,. Early triptan intervention in migraine: An overview. Neurol Sci. 2005; 26 (Suppl. 2): 108-110.
49. Kwong WJ, Taylor FR, Adelman JU,. The effect of early intervention with sumatriptan tablets on migraine-associated productivity loss. Occup Environ Med. 2005; 47: 1167-1173. (Pubitemid 41642508)
50. Foley KA, Cady R, Martin V, et al,. Treating early versus treating mild: Timing of migraine prescription medications among patients with diagnosed migraine. Headache. 2005; 45: 538-545. (Pubitemid 40847178)
51. Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR,. Eletriptan in the early treatment of acute migraine: Influence of pain intensity and time of dosing. Cephalalgia. 2005; 25: 735-742. (Pubitemid 41208315)
52. Winner P, Landy S, Richardson M, Ames M,. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: A pooled analysis of data from six clinical trials. Clin Ther. 2005; 27: 1785-1794. (Pubitemid 41815229)